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IT has been reported by some workers that the concentration of serum muco-
protein is markedly increased in animals with experimental tumours, and also
that the mucoprotein content ofthe serum and urine steadily rises in patients with
malignant tumours. The increase in acid mucopolysaccharide concentration was
observed in human patients with proliferating malignant tumours (Deutsch,
1957; Bergsterman, 1955). Rich and Meyers reported that excretion of acid
mucopolysaccharides in the urine of patients with malignant neoplastic diseases
showed a significant increase, and that acid mucopolysaccharides isolated from the
urine ofseveral patients with cancer or leukemia were found to have a composition
mainly similar to that of chondroitin sulphate (Rich and Meyers, 1959).
The present author (Takeuchi 1965, 1966a, 1966b) reported that acid muco-
polysaccharides promoted the growth of solid Ehrlich ascites tumour when the
subcutaneous injection of acid mucopolysaccharide solution was immediately
followed by tumour inoculation into the same site, and that the tumour growth
tended to be accelerated asthe concentration ofchondroitin sulphate inthetumour
inoculation site was increased.
In the present study the author has investigated the effect of continuous
administration of chondroitin sulphate in order to elucidate its promoting activity
on the growth ofsolid Ehrlich ascites tumour. This paper reports that the growth
of solid Ehrlich ascites tumour is related to the increase in urinary excretion of
chondroitin sulphate daily injected into the peritoneal cavity or subcutaneous
space ofmice.
MATERIALS AND METHODS
Tumour cells used in this study were ofEhrlich hypotetraploid stock Kaziwara
4N (Kaziwara, 1954) maintained intraperitoneally in SM male mice through
serial transplantation at 7- or 8-day intervals in this laboratory.
Animals were male SM mice, obtained from the centre supplying laboratory
animals in this medical school. They were fed with a standard pellet diet (CA-1,
Nihon Clea Co., Ltd., Tokyo) and given drinking water ad libitum. In all mice of
this strain, solid Ehrlich ascites tumours developed at the site of the inoculation;
the growth of the tumour was greater in males than in females, as described in a
previous paper (Takeuchi et al., 1965).
Subcutaneous or intraperitoneal injection of chondroitin sulphate, one ml. of
2% chondroitin sulphate/day/mouse, was started on day 0, and terminated on
day 10, a total of 11 injections. Chondroitin sulphate (average molecular weight
50,000) was obtained from Kaken Yakukako Co., Ltd., Tokyo. In the control,
1 ml. of isotonic saline was daily injected intraperitoneally. On day 3, Ehrlich
ascitic tumour cells, 5 X 106/mouse, were inoculated into the subcutaneous spaceEFFECT OF CHONDROITIN SULPHATE ON TUMOUR GROWTH
ofright side back ofthe mice, and the tumour-bearing animals were killed on day
11. The results of this experiment were evaluated on the basis of the average
weight of tumour tissue in the experimental as compared with the control group.
The concentration ofchondroitin sulphate in the urine ofthe mice was checked
as follows. The urine of the chondroitin sulphate-treated and control mice was
collectedby amicropipetteperiodically, and 0.01 ml. each was put on a filter paper
(Toyo Filter Paper No. 51, Toyo Roshi Kaisha, Ltd), and was stained with tolui-
dine blue by Leitner and Kerby's method (Leitner and Kerby, 1954). The
density of the metachromatically coloured spot on the filter paper, embedded in
paraffin, was read with a densitometer (Toyo Direct Reading Type Paper Densi-
tometer, Red Filter). By this staining the metachromatically coloured spot of
0-02 ml. of chondroitin sulphate solution on the filter paper could be seen even in
the case of a 1: 128 dilution of the 1% solution, as shown in a previous paper
(Takeuchi, 1961).
RESULTS
Solid Ehrlich ascites tumour was developed by subcutaneous injection of
ascitic tumour cells in all mice used in this experiment.
TABLE I.-Effect ofIntraperitoneal andSubcutaneous Injection ofChondroitin
Sulphate on Growth of Solid Ehrlich Ascites Tumour on the 8th Day After
Tumour Inoculation
Exp. No. . . . 1 . 2 . 3 . 4 . 5. Totals
No. of Mice i.p. inject.. 10 . 14 11 . 5 . 12 . 52
of chondr. S.
Tumour weight % . 131 . 159 . 147 . 129 . 136 . 139
(control 100)
No. of mices.C. inject . 10 . 15 . 11 . 6 . 12 . 54
of chondr. S.
Tumour weight % . 104 . 145 . 106 . 113 . 106 . 121
(control 100)
No. of mice control . 10 . 15 . 10 . 8 . 12 55
Average Taimour Weight -I- S.E. based on (n) P*
Intraperitoneal injection of 1198 4- 76 mg. (52) 0.001 < P < 0.005
chondroitin sulphate /
Subcutaneous injection of 1045 4- 64mg. (54) / 0*02 <.P < 0 05
chondroitin sulphate
Control 860 4- 59 mg. (55)
P*: The evaluation was based on the Student's t-test..
Table I shows the relation between the injection sites of chondroitin sulphate
and the growth of tumour. It is indicated that intraperitoneal injection of
chondroitin sulphate accelerates the growth of tumour to some extent, but that
the effect of hypodermal injection of the same agent is rather ambiguous. When
1 ml. of2% chondroitin sulphatewas intraperitoneally injected daily the difference
of tumour weight between chondroitin sulphate-treated group and control group
was statistically significant, while the difference of tumour weight between these
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2 groups was scarcely observed in the case of daily hypodermal injection of 1 ml.
of 2% chondroitin sulphate.
The presence of chondroitin sulphate in the urine ofmice which were injected
with 1 ml. of2% chondroitin sulphate solution intraperitoneally orsubcutaneously
was indicated on the filter paper as a metachromatically coloured spot. As
shown in Fig. 1, the concentration of chondroitin sulphate in the urine of intra-
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FIG. I.-Density ofmetachromatically coloured spot of chondroitin sulphate in urine of mice
injectedintraperitoneally(i.p.) orsubcutaneously(s.C.) with I ml. of2% chondroitin sulphate
solution. These values were average for 13 mice.
peritoneally chondroitin sulphate-injected mice was higher than that of sub-
cutaneously inj'ected mice, and the difference of concentration between the intra-
peritoneally treated group and the subcutaneously treated group became distinct
3 hours after chondroitin sulphate injection. No coloured spot was developed
from the urine of control mice by this method.
DISCUSSION
The present study indicates that intraperitoneal injection of chondroitin
sulphate accelerates the growth of tumour to some exrtent, but that the effect of
hypodermal injection ofthe same agent is indistinct, and also that the concentra-
tion of chondroitin sulphate in the urine of intraperitoneally inj'ected mice is
higher than that ofsubcutaneously injected ones.
Kamei (1964) also reported that intraperitoneal injection of chondroitin
sulphate promoted the growth ofsolid Yoshida ascites tumour in rats.
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Ozzello et al. (1960) noticed the growth-promoting activity of acid muco-
polysaccharides in vitro on a strain of human mammary carcinoma cells, their
growth being in parallel with the rise in the concentration of acid mucopoly-
saccharides in the culture medium. The present author (Takeuchi 1966a, 1966b)
reported that tumour growth in mice was accelerated in accordance with the
increase in the concentration or amount ofchondroitin sulphate solution which was
injected prior to tumour inoculation into the same site.
A greater tumour-growth promoting effect of intraperitoneal injection of
chondroitin sulphate as compared with the subcutaneous injection may be related
to the chondroitin sulphate level in the serum ofthe mouse which, inferring from
the concentration ofthe excreted chondroitin sulphate in the urine, is much higher
in the intraperitoneal group than in the subcutaneous group.
The exact mechanism of the action of chondroitin sulphate on the growth of
tumour is beyond the scope of the present study. However, the data obtained
indicated that higher concentrations of acid mucopolysaccharides in the serum of
mice is favourable to the growth of cancer cells.
SUMMARY
Using solid Ehrlich ascites tumour developed subcutaneously in SM mice, the
effect of continuous administration of chondroitin sulphate on the growth of
tumour and the relation between tumour growth and urinary excretion of chond-
roitin sulphate were studied.
It was observed that intraperitoneal injection of 1 ml. of 2% chondroitin
sulphate accelerates the growth of tumour to some extent, but that the effect of
hypodermal injection of the same agent is rather ambiguous. It was also shown
that the concentration of chondroitin sulphate in the urine of intraperitoneally
chondroitin sulphate-injected mice was higher than that of subcutaneously
injected mice.
There may be some relationship between a greater tumour growth promoting
effect of intraperitoneal injection of chondroitin sulphate as compared with
subcutaneous injection and the chondroitin sulphate level in serum of the mouse
which, inferring from the concentration of the excreted chondroitin sulphate in
urine, is much higher in the intraperitoneal group than in the subcutaneous group.
The author owes a debt of gratitude to Prof. H. Tauchi for his advice and
encouragement, and also to Dr. M. Kodama, Aichi Cancer Center Research
Institute, for fruitful discussions of the problems.
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